Somapacitan - Growth failure - adults

You are here : Home > Formulary Search > Somapacitan - Growth failure - adults

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Status 1

See narrative

Formulations :

No records returned.

Formulary Status :

Primary Care

ASPH

RSFT

SASH

SABP

Associated Icons :

NFD2

SPC

Restrictions / Comments :

Important

This drug has not yet been assessed for formulary status. Contact your pharmacy team for advice on making an application to APC.

Documentation

No records returned.

PAD Profile

ChemicalSubstance :

Somapacitan

Indication :

Growth failure - adults

Group Name :

Keywords :

Brand Names Include :

Sogroya

Important Information :

Latest Additions Date From :

Latest Additions Date To :

Guidelines :

Supporting Documents :

Other Indications

Below are listed other indications that Somapacitan is used to treat.

Growth failure - children

Other Drugs

Below are listed other drugs that are used to treat Growth failure - adults.

Somatropin

Committee Recommendations (1)

09 Oct 24 - Not Set

This drug has not yet been assessed for formulary status.
It has not yet been evaluated by NICE or the Surrey Heartlands ICS Area Prescribing Committee (APC). As such, advice regarding safety, effectiveness (including cost-effectiveness) and its place in therapy is yet to be determined.
Before prescribing this drug/device it is recommended that clinicians contact their Medicines Optimisation team to discuss possible alternatives/options.

NICE are due to publish guidance on this drug (date tbc) and this will be considered by the APC within 90 days of publication.